Rallybio (RLYB) Operating Leases (2022 - 2026)

Rallybio (RLYB) posted Operating Leases of $55000.0 for Q1 2026, down 32.93% sequentially from $82000.0 in Q4 2025.

Rallybio (RLYB) Operating Leases (2022 - 2026) Analysis & Trends

Rallybio has reported Operating Leases for 5 years, with the latest figure at $55000.0 in Q1 2026.

Quarterly Operating Leases changed N/A year-over-year to $55000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $55000.0 (changed N/A YoY) and the FY2025 annual result came in at $82000.0, changed N/A from the prior year.
Operating Leases slipped to $55000.0 in Q1 2026 per RLYB's latest filing, from $82000.0 in the prior quarter.
Over five years, Operating Leases peaked at $555000.0 in Q4 2022 and troughed at $55000.0 in Q1 2026.
A 5-year average of $275923.1 and a median of $266000.0 in 2023 frame the typical range for Operating Leases.
The sharpest annual moves came in 2023 and 2024: Operating Leases declined 29.37% in 2023, then tumbled 78.2% in 2024.
Over 5 years, Operating Leases stood at $555000.0 in 2022, then slipped by 29.37% to $392000.0 in 2023, then plunged by 85.2% to $58000.0 in 2024, then surged by 41.38% to $82000.0 in 2025, then slumped by 32.93% to $55000.0 in 2026.
According to Business Quant data, Operating Leases over the past three periods registered $55000.0, $82000.0, and $108000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Rallybio	94.61 Mn	94.61 Mn	-

Download Data